<DOC>
	<DOCNO>NCT02054806</DOCNO>
	<brief_summary>This study ass efficacy safety pembrolizumab ( MK-3475 ) administer participant incurable advanced biomarker-positive solid tumor respond current therapy current therapy appropriate . The study hypothesis administration pembrolizumab participant type solid tumor result clinically meaningful response rate .</brief_summary>
	<brief_title>Study Pembrolizumab ( MK-3475 ) Participants With Advanced Solid Tumors ( MK-3475-028/KEYNOTE-28 )</brief_title>
	<detailed_description />
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>Histologically cytologically document locallyadvanced and/or metastatic solid malignancy incurable , fail prior standard therapy standard therapy appropriate Have biomarkerpositive solid tumor Have measurable disease base Response Criteria Solid Tumors Version 1.1 ( RECIST 1.1 ) Eastern Cooperative Oncology Group ( ECOG ) Performance status 0 1 Adequate organ function Female participant childbearing potential must willing use adequate method contraception course study 120 day last dose study medication Male participant childbearing potential must agree use adequate method contraception start first dose study medication 120 day last dose study medication Is currently participate receive study therapy participate study investigational agent receive study therapy use investigational device within 4 week first dose treatment Diagnosis immunodeficiency receive systemic steroid therapy form immunosuppressive therapy within 7 day prior first dose trial treatment Prior anticancer therapy monoclonal antibody ( mAb ) within 4 week prior study Day 1 recover adverse event due mAbs administer 4 week earlier Prior chemotherapy , target small molecule therapy , radiation therapy within 2 week ( 12 week measurable site central nervous system [ CNS ] disease ) prior study Day 1 recover adverse event due previously administer agent Known additional malignancy progress require active treatment except basal cell carcinoma skin , squamous cell carcinoma skin undergone potentially curative therapy , situ cervical cancer Known active CNS metastasis and/or carcinomatous meningitis Has active autoimmune disease require systemic treatment past 2 year ( i.e . use disease modify agent , corticosteroid immunosuppressive drug ) . Replacement therapy ( e.g. , thyroxine , insulin , physiologic corticosteroid replacement therapy adrenal pituitary insufficiency , etc . ) consider form systemic treatment Has evidence interstitial lung disease history ( noninfectious ) pneumonitis require steroid current pneumonitis Active infection require systemic therapy Known psychiatric substance abuse disorder would interfere cooperation requirement trial Pregnant , breastfeeding , expect conceive father child within project duration trial , start prescreening screen visit 120 day last dose trial treatment Has previously participate pembrolizumab ( MK3475 ) trial , receive prior therapy antiPD1 , antiPDL1 , antiPDL2 ( include ipilimumab antibody drug specifically target Tcell costimulation checkpoint pathway ) Known history human immunodeficiency virus ( HIV ) Known active Hepatitis B Hepatitis C Has receive live vaccine within 30 day plan start study medication . Examples live vaccine include , limited , follow : measles , mumps , rubella , varicella/zoster ( chicken pox ) , yellow fever , rabies , Bacillus CalmetteGuérin ( BCG ) , typhoid vaccine . Seasonal influenza vaccine injection generally kill virus vaccine allow ; however , intranasal influenza vaccine ( e.g . FluMist® ) live attenuate vaccine allow .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>PD1</keyword>
	<keyword>PD-1</keyword>
	<keyword>PDL1</keyword>
	<keyword>PD-L1</keyword>
</DOC>